@article{3107997,
    title = "Long-term safety of deferiprone treatment in children from the mediterranean region with beta-thalassemia major: The DEEP-3 multi-center observational safety study",
    author = "Botzenhardt, S. and Felisi, M. and Bonifazi, D. and Del Vecchio, G.C. and Putti, M.C. and Kattamis, A. and Ceci, A. and Wong, I.C.K. and Neubert, A. and DEEP consortium (collaborative group)",
    journal = "Haematologica-the hematology journal",
    year = "2018",
    volume = "103",
    number = "1",
    pages = "e1-e4",
    publisher = "Ferrata Storti Foundation",
    doi = "10.3324/haematol.2017.176065",
    keywords = "alanine aminotransferase;  deferiprone;  deferiprone;  iron chelating agent, abdominal pain;  agranulocytosis;  alanine aminotransferase level;  Albania;  aminotransferase blood level;  arthralgia;  arthropathy;  beta thalassemia;  blood transfusion;  body weight gain;  chelation therapy;  child;  cohort analysis;  Cyprus;  diarrhea;  drug safety;  drug withdrawal;  dyspepsia;  Egypt;  endocrine disease;  fatigue;  female;  follow up;  Greece;  hearing impairment;  heart disease;  hospitalization;  human;  hypersalivation;  incidence;  iron chelation;  Italy;  joint swelling;  kidney dysfunction;  knee;  Letter;  leukopenia;  long term care;  major clinical study;  male;  monotherapy;  multicenter study;  nausea and vomiting;  neurologic disease;  neutropenia;  observational study;  preschool child;  school child;  skin manifestation;  Southern Europe;  splenectomy;  splenomegaly;  thrombocytopenia;  Tunisia;  age;  beta thalassemia;  clinical trial;  complication;  iron overload;  Southern Europe;  treatment outcome, Age Factors;  beta-Thalassemia;  Child;  Deferiprone;  Humans;  Iron Chelating Agents;  Iron Overload;  Mediterranean Region;  Treatment Outcome"
}